Vertex Pharmaceuticals, FDA

Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?
Vertex Pharmaceuticals ( VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings. But Vertex now is showing that it also can be a game changer when it comes to treating one of the most common of health problems -- pain.
Vertex Pharmaceuticals stock is soaring. The FDA just approved its potentially game-changing pain treatment.
Shares of Vertex Pharmaceuticals Inc. surged ahead of Friday’s market open after the Food and Drug Administration approved the company’s non-opioid pain treatment.
Vertex Pharmaceuticals (VRTX) Set for Painless Gains After FDA Approval
Vertex Pharmaceuticals (VRTX) stock has performed strongly since the turn of the year, gaining 14.6% and vastly outperforming the healthcare
Vertex Pharmaceuticals Just Won a Huge FDA Approval. Is the Biotech Stock a No-Brainer Buy?
Vertex Pharmaceuticals (NASDAQ: VRTX) just snagged its second U.S. Food and Drug Administration (FDA) approval in only 41 days. On Dec. 20, 2024, the FDA gave a thumbs-up to Alyftrek in treating cystic fibrosis (CF).
Vertex Pharma Stock Surges After FDA Approves Non-Opioid Pain Drug
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Vertex Pharmaceuticals' non-opioid pain medication gets FDA approval
A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA).
Is Vertex Pharmaceuticals a Buy Now That the FDA Approved Its New Pain Drug?
Lately, one of America's leading pharmaceutical companies can't catch a break from Wall Street. Shares of Vertex Pharmaceuticals (NASDAQ: VRTX) are down about 9% from a peak the stock set in November,
How Painkillers Could Be Vertex Pharmaceuticals' Next $10 Billion Chapter
Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day
Shares of Vertex Pharmaceuticals Inc. VRTX rallied 2.53% to $482.28 Tuesday, on what proved to be an all-around great trading ...
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $4,232.95 today based on a ...
What's Happening With VRTX Stock?
With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...
Is Vertex Pharmaceuticals Stock a Buy in 2025?
The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...
Vertex Pharmaceuticals: Strong Buy Rating Driven by Suzetrigine Approval and Promising Market Prospects
Leerink Partners analyst David Risinger has reiterated their bullish stance on VRTX stock, giving a Buy rating on January 31.Maximize Your ...
American Association of Individual Investors6d
Which Is a Better Investment, Natera, Inc. or Vertex Pharmaceuticals Incorporated Stock?
Learn more about whether Natera, Inc. or Vertex Pharmaceuticals Incorporated is a better investment based on AAII's A+ ...